近日,第一三共宣布[1],其研发的靶向HER3的抗体偶联药物(ADC)patritumab deruxtecan(U3-1402)挺进结直肠癌(CRC)的II期临床,评估U3-1402治疗晚期、转移性、耐药、难治性或复发性结直肠癌的研究正在开展。这是U3-1402在拿下肺乳两大癌种初期疗效数据后进一步向结直肠癌第三大癌种进发!为HER3这样一个新型靶点...
近日,第一三共宣布[1],其研发的靶向HER3的抗体偶联药物(ADC)patritumab deruxtecan(U3-1402)挺进结直肠癌(CRC)的II期临床,评估U3-1402治疗晚期、转移性、耐药、难治性或复发性结直肠癌的研究正在开展。这是U3-1402在拿下肺乳两大癌种初期疗效数据后进一步向结直肠癌第三大癌种进发!为HER3这样一个新型靶点...
HER3 (human epidermal growth factor receptor 3) is overexpressed in several cancers including colorectal cancer (CRC). Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody-drug conjugate (ADC), ...
近日,第一三共宣布[1],其研发的靶向HER3的抗体偶联药物(ADC)patritumab deruxtecan(U3-1402)挺进结直肠癌(CRC)的II期临床,评估U3-1402治疗晚期、转移性、耐药、难治性或复发性结直肠癌的研究正在开展。这是U3-1402在拿下肺乳两大癌种初期疗效数据后进一步向结直肠癌第三大癌种进发!为HER3这样一个新型靶点...
An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC) TPS157 Background: Patritumab deruxtecan (HER3-DXd; U3-1402) is a novel, investigational antibody drug conjugate comprising an an...
SJ Pearton - 《Crc Press》 被引量: 196发表: 1997年 Smart composite structures with embedded sensors Fiber-optic sensors embedded within advanced composite materials represent a new branch of engineering with the potential to greatly enhance the confidence... RM Measures - 《Composites Engineering》...